Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYR-PB21 vs bupivacaine for postoperative analgesia after hallux valgus osteotomy
CTR20243500Phase 2Completed
- Sponsor
- Hefei Cosource Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HYR-PB21 in postoperative pain (2 arms), sponsored by Hefei Cosource Pharmaceutical. Primary endpoint: Primary: AUC of resting pain intensity over 0–72 hours. Started Sep 2024; status: completed.
02
Drugs
HYR-PB21
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20243500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243500.